Title: Overview of the biotech drug development pathway
Duration: 58 minutes - Available On Demand
Biopharmaceuticals consist of some of the top blockbuster medicinal products in the industry. Biotechnology product development for major markets such as US/EU as well as other regions of the world is continuing to increase. Analysis shows that developers who prepare global upfront strategies and utilize risk-based tools benefit from efficiency and save resources leading to faster market entry.
- Overview of the multidisciplinary (CMC, non-clinical and clinical) requirements for the development of biotech products
Highlight of all critical requirements
Summary of common CMC pitfalls and how to avoid them
Director, Regulatory Affairs, PharmaLex
Zeb Younes has over 16 years of experience in biopharmaceutical / biosimilar development lifecycle from proof of concept through to, and beyond commercialization with both laboratory and desk based experience in process development, purification, formulation, method development, characterisation, validation, comparability, release and stability testing. Zeb has experience with ATMPs, vaccines, recombinant proteins including monoclonal antibodies and derivatives and over 10 different biosimilar products.